New Stock News | Huarong Biology submits third prospectus to Hong Kong Stock Exchange. Pro-101-1 for treating burns and scalds has completed phase IIb clinical trials in China.

According to the Zhitong Financial APP, it was disclosed by the Hong Kong Stock Exchange on August 15th that Huaren Biological Technology (Qingdao) Co., Ltd. (referred to as: Huaren Biological) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Huatai International and CITIC Securities as joint sponsors. The company had previously submitted applications to the Hong Kong Stock Exchange on April 29, 2024 and November 22, 2024.